HC Wainwright & Co. Reiterates Buy on Syndax Pharmaceuticals, Maintains $41 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has reiterated its Buy rating on Syndax Pharmaceuticals (NASDAQ:SNDX) and maintained a price target of $41.
August 02, 2024 | 12:04 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated its Buy rating on Syndax Pharmaceuticals and maintained a price target of $41, indicating confidence in the company's future performance.
The reiteration of a Buy rating and maintenance of a $41 price target by HC Wainwright & Co. suggests strong confidence in Syndax Pharmaceuticals' future performance. This positive analyst rating is likely to boost investor sentiment and could lead to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100